Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib

被引：18

作者：

Ariyasu, Ryo ^{[1
]}

Horiike, Atsushi ^{[1
]}

Koyama, Junji ^{[1
]}

Saiki, Masafumi ^{[1
]}

Sonoda, Tomoaki ^{[1
]}

Kawashima, Yosuke ^{[1
]}

Takano, Natsuki ^{[1
]}

Oguri, Tomoyo ^{[1
]}

Nishikawa, Shingo ^{[1
]}

Kitazono, Satoru ^{[1
]}

Yanagitani, Noriko ^{[1
]}

Ohyanagi, Fumiyoshi ^{[1
]}

Nishio, Makoto ^{[1
]}

机构：

[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan

来源：

ANTI-CANCER DRUGS | 2017年 / 28卷 / 05期

关键词：

bevacizumab; epithelial growth factor receptor tyrosine kinase inhibitor; erlotinib; leptomeningeal carcinomatosis; non-small-cell lung cancer; CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; METASTASES; RESISTANCE; IMPACT;

D O I：

10.1097/CAD.0000000000000489

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In patients with non-small-cell lung cancer harboring an epithelial growth factor receptor (EGFR) active mutation, central nervous system progression after a response to EGFR tyrosine kinase inhibitors is frequent. Central nervous system metastasis, especially leptomeningeal carcinomatosis (LMC), is a serious complication and no standard treatment has been established for LMC. Here, we report two cases in which the addition of bevacizumab to erlotinib enhanced the efficacy against LMC; as a result, radiographic abnormalities decreased markedly and symptoms were well controlled. This combination treatment may be useful to treat LMC in patients with EGFR-positive non-small-cell lung cancer.

引用

页码：565 / 567

页数：3

共 9 条

[1] Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study [J].

Besse, Benjamin ;

Le Moulec, Sylvestre ;

Mazieres, Julien ;

Senellart, Helene ;

Barlesi, Fabrice ;

Chouaid, Christos ;

Dansin, Eric ;

Berard, Henri ;

Falchero, Lionel ;

Gervais, Radj ;

Robinet, Gilles ;

Ruppert, Anne-Marie ;

Schott, Roland ;

Lena, Herve ;

Clement-Duchene, Christelle ;

Quantin, Xavier ;

Souquet, Pierre Jean ;

Tredaniel, Jean ;

Moro-Sibilot, Denis ;

Perol, Maurice ;

Madroszyk, Anne-Catherine ;

Soria, Jean-Charles .

CLINICAL CANCER RESEARCH, 2015, 21 (08) :1896-1903

[2] Revacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy [J].

Dickson, Paxton V. ;

Hamner, John B. ;

Sims, Thomas L. ;

Fraga, Charles H. ;

Ng, Catherine Y. C. ;

Rajasekeran, Surender ;

Hagedorn, Nikolaus L. ;

McCarville, M. Beth ;

Stewart, Clinton F. ;

Davidoff, Andrew M. .

CLINICAL CANCER RESEARCH, 2007, 13 (13) :3942-3950

[3]

Hata A, 2015, ANTICANCER RES, V35, P1025

[4] Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis:: diagnostic and prognostic value [J].

Herrlinger, U ;

Wiendl, H ;

Renninger, M ;

Förschler, H ;

Dichgans, J ;

Weller, M .

BRITISH JOURNAL OF CANCER, 2004, 91 (02) :219-224

[5] Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors [J].

Lee, Su Jin ;

Lee, Jung-Il ;

Nam, Do-Hyun ;

Ahn, Young Chan ;

Han, Jung Ho ;

Sun, Jong-Mu ;

Ahn, Jin Seok ;

Park, Keunchil ;

Ahn, Myung-Ju .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (02) :185-191

[6] Frequent Central Nervous System Failure After Clinical Benefit With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Korean Patients With Nonsmall-Cell Lung Cancer [J].

Lee, Young Joo ;

Choi, Hye Jin ;

Kim, Se Kyu ;

Chang, Joon ;

Moon, Jin Wook ;

Park, In Kyu ;

Kim, Joo-Hang ;

Cho, Byoung Chul .

CANCER, 2010, 116 (05) :1336-1343

[7] Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy [J].

Masuda, Takeshi ;

Hattori, Noboru ;

Hamada, Akinobu ;

Iwamoto, Hiroshi ;

Ohshimo, Shinichiro ;

Kanehara, Masashi ;

Ishikawa, Nobuhisa ;

Fujitaka, Kazunori ;

Haruta, Yoshinori ;

Murai, Hiroshi ;

Kohno, Nobuoki .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) :1465-1469

[8] Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance [J].

Naumov, George N. ;

Nilsson, Monique B. ;

Cascone, Tina ;

Briggs, Alexandra ;

Straume, Oddbjorn ;

Akslen, Lars A. ;

Lifshits, Eugene ;

Byers, Lauren Averett ;

Xu, Li ;

Wu, Hua-Kang ;

Janne, Pasi ;

Kobayashi, Susumu ;

Halmos, Balazs ;

Tenen, Daniel ;

Tang, Xi M. ;

Engelman, Jeffrey ;

Yeap, Beow ;

Folkman, Judah ;

Johnson, Bruce E. ;

Heymach, John V. .

CLINICAL CANCER RESEARCH, 2009, 15 (10) :3484-3494

[9] Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study [J].

Seto, Takashi ;

Kato, Terufumi ;

Nishio, Makoto ;

Goto, Koichi ;

Atagi, Shinji ;

Hosomi, Yukio ;

Yamamoto, Noboru ;

Hida, Toyoaki ;

Maemondo, Makoto ;

Nakagawa, Kazuhiko ;

Nagase, Seisuke ;

Okamoto, Isamu ;

Yamanaka, Takeharu ;

Tajima, Kosei ;

Harada, Ryosuke ;

Fukuoka, Masahiro ;

Yamamoto, Nobuyuki .

LANCET ONCOLOGY, 2014, 15 (11) :1236-1244

← 1 →